Research Endpoints will manage the growing demand for the Scottsdale, Arizona-based firm's imaging research and biomarker business, according to an announcement made Wednesday.
Growing imaging workloads and clear patient benefits should encourage rads to see this as an opportunity rather than a turf threat, two experts argued in a new editorial.